MVCD7
MCID: MCR120
MIFTS: 47

Microvascular Complications of Diabetes 7 (MVCD7)

Categories: Cardiovascular diseases, Eye diseases, Genetic diseases, Nephrological diseases, Neuronal diseases

Aliases & Classifications for Microvascular Complications of Diabetes 7

MalaCards integrated aliases for Microvascular Complications of Diabetes 7:

Name: Microvascular Complications of Diabetes 7 57 72 29 13 6
Diabetic Nephropathy 72 70
Mvcd7 57 72
Microvascular Complications of Diabetes, Susceptibility to, 7 57
Nonproliferative Retinopathy, Diabetic, Susceptibility to 57
Proliferative Retinopathy, Diabetic, Susceptibility to 57
Microvascular Complications of Diabetes, Type 7 39
Nephropathy, Diabetic, Susceptibility to 57
Nonproliferative Retinopathy, Diabetic 57
Diabetic Non-Proliferative Retinopathy 72
Proliferative Retinopathy, Diabetic 57
Proliferative Diabetic Retinopathy 70
Diabetic Proliferative Retinopathy 72
Nephropathy, Diabetic 57

Classifications:



External Ids:

OMIM® 57 612635
OMIM Phenotypic Series 57 PS603933
MeSH 44 D048909
UMLS 70 C0011881 C0154830

Summaries for Microvascular Complications of Diabetes 7

UniProtKB/Swiss-Prot : 72 Microvascular complications of diabetes 7: Pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.

MalaCards based summary : Microvascular Complications of Diabetes 7, also known as diabetic nephropathy, is related to microvascular complications of diabetes 1 and hemochromatosis, type 1. An important gene associated with Microvascular Complications of Diabetes 7 is HFE (Homeostatic Iron Regulator). The drugs Clopidogrel and Methylcobalamin have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and pancreas.

More information from OMIM: 612635 PS603933

Related Diseases for Microvascular Complications of Diabetes 7

Diseases in the Microvascular Complications of Diabetes 1 family:

Microvascular Complications of Diabetes 2 Microvascular Complications of Diabetes 3
Microvascular Complications of Diabetes 4 Microvascular Complications of Diabetes 5
Microvascular Complications of Diabetes 6 Microvascular Complications of Diabetes 7

Diseases related to Microvascular Complications of Diabetes 7 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 431)
# Related Disease Score Top Affiliating Genes
1 microvascular complications of diabetes 1 31.8 HFE-AS1 HFE
2 hemochromatosis, type 1 29.4 HFE-AS1 HFE
3 transferrin serum level quantitative trait locus 2 29.3 HFE-AS1 HFE
4 porphyria cutanea tarda 29.3 HFE-AS1 HFE
5 alzheimer disease 29.2 HFE-AS1 HFE
6 variegate porphyria 29.2 HFE-AS1 HFE
7 cystic fibrosis 29.1 HFE-AS1 HFE
8 microvascular complications of diabetes 2 11.5
9 type 1 diabetes mellitus 11.4
10 microvascular complications of diabetes 3 11.3
11 microvascular complications of diabetes 4 11.3
12 microvascular complications of diabetes 6 11.3
13 diabetic angiopathy 11.1
14 maturity-onset diabetes of the young 11.1
15 hyperglycemia 11.1
16 renal fibrosis 11.0
17 type 2 diabetes mellitus 11.0
18 diabetes mellitus 11.0
19 fibrosis of extraocular muscles, congenital, 1 10.9
20 chronic kidney disease 10.9
21 glomerulonephritis 10.8
22 lipid metabolism disorder 10.8
23 nephrotic syndrome 10.7
24 vascular disease 10.7
25 uremia 10.6
26 hypertension, essential 10.6
27 iga glomerulonephritis 10.6
28 membranous nephropathy 10.5
29 neuropathy 10.5
30 peripheral vascular disease 10.5
31 arteriosclerosis 10.5
32 glomerular disease 10.5
33 kidney hypertrophy 10.5
34 autonomic neuropathy 10.5
35 hyperinsulinism 10.4
36 diabetic neuropathy 10.4
37 pre-eclampsia 10.4
38 nephrosclerosis 10.4
39 hypoglycemia 10.4
40 cytokine deficiency 10.4
41 hypercholesterolemia, familial, 1 10.4
42 hyperuricemia 10.4
43 rickets 10.4
44 congestive heart failure 10.4
45 hypertriglyceridemia, familial 10.4
46 proteasome-associated autoinflammatory syndrome 1 10.4
47 acute kidney failure 10.4
48 yemenite deaf-blind hypopigmentation syndrome 10.4
49 muscle hypertrophy 10.4
50 glucose intolerance 10.4

Comorbidity relations with Microvascular Complications of Diabetes 7 via Phenotypic Disease Network (PDN): (show all 11)


Acute Cystitis Chronic Kidney Disease
Deficiency Anemia Diabetic Cataract
Diabetic Polyneuropathy Heart Disease
Hypertension, Essential Hypoglycemia
Microvascular Complications of Diabetes 1 Peripheral Vascular Disease
Rubeosis Iridis

Graphical network of the top 20 diseases related to Microvascular Complications of Diabetes 7:



Diseases related to Microvascular Complications of Diabetes 7

Symptoms & Phenotypes for Microvascular Complications of Diabetes 7

Clinical features from OMIM®:

612635 (Updated 05-Apr-2021)

Drugs & Therapeutics for Microvascular Complications of Diabetes 7

Drugs for Microvascular Complications of Diabetes 7 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 314)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
2
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
3
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
4
Zaleplon Approved, Illicit, Investigational Phase 4 151319-34-5 5719
5
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
6
Bevacizumab Approved, Investigational Phase 4 216974-75-3
7
Enalaprilat Approved Phase 4 76420-72-9 6917719
8
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
9
Doxazosin Approved Phase 4 74191-85-8 3157
10
Simvastatin Approved Phase 4 79902-63-9 54454
11
Ramipril Approved Phase 4 87333-19-5 5362129
12
Liraglutide Approved Phase 4 204656-20-2 44147092
13
Dipivefrin Approved Phase 4 52365-63-6 3105
14
Insulin glargine Approved Phase 4 160337-95-1
15
Insulin glulisine Approved Phase 4 207748-29-6
16
carbamide peroxide Approved Phase 4 124-43-6
17
Probucol Approved, Investigational Phase 4 23288-49-5 4912
18
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
19
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
20
Nisoldipine Approved Phase 4 63675-72-9 4499
21
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
22
Atorvastatin Approved Phase 4 134523-00-5 60823
23
Indapamide Approved Phase 4 26807-65-8 3702
24
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
25
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
26
Amlodipine Approved Phase 4 88150-42-9 2162
27
Clonidine Approved Phase 4 4205-90-7 2803
28
Atenolol Approved Phase 4 29122-68-7 2249
29
Trandolapril Approved Phase 4 87679-37-6 5484727
30
Verapamil Approved Phase 4 52-53-9 2520
31
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
32
Saxagliptin Approved Phase 4 361442-04-8 11243969
33
Insulin lispro Approved Phase 4 133107-64-9
34
Metformin Approved Phase 4 657-24-9 4091 14219
35
Captopril Approved Phase 4 62571-86-2 44093
36
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
37
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
38
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
39
Niclosamide Approved, Investigational, Vet_approved Phase 4 50-65-7 4477
40
Lomustine Approved, Investigational Phase 4 13010-47-4 3950
41
tannic acid Approved Phase 4 1401-55-4
42
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
43
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
44
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
45
Losartan Approved Phase 4 114798-26-4 3961
46
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
47
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
48
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 70-16-6, 59-43-8 1130
49
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 11103-57-4 445354
50
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181

Interventional clinical trials:

(show top 50) (show all 412)
# Name Status NCT ID Phase Drugs
1 A Prospective, Randomized, Two Period, With an Intermediate Wash Out Period, Cross-over Study to Compare the Effects of Either Combined Therapy With Ramipril and Clopidogrel or Ramipril Monotherapy on Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Patients With Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4 Ramipril;Clopidogrel
2 Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy Unknown status NCT01673204 Phase 4 Calcitriol;Placebo
3 Effect of Intravenous and Oral Therapy With Sulodexide on Albuminuria in Type 2 Diabetic Patients Unknown status NCT01316068 Phase 4 intravenous use of sulodexide followed by oral use;use of sulodexide orally only
4 A Pilot Study to Determine if Intravitreal Injections of Pegaptanib Sodium (Macugen) Given Every 12 Weeks for a Year After an Induction Phase of Three Injections Every 6 Weeks Will Reduce the Progression of Proliferative Diabetic Retinopathy in Patients Without Significant Vitreous Hemorrhage in Comparison to Treatment With Retinal Photocoagulation Alone and After an Induction Phase Unknown status NCT01486771 Phase 4 Macugen ® (pegaptanib sodium)
5 Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy Unknown status NCT01921192 Phase 4 Folic Acid, vit B6 and B12;Placebo
6 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Macular Edema Post Treatment. Unknown status NCT00563628 Phase 4
7 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Electroretinograms and Contrast Sensitivity Post Treatment. Unknown status NCT00563043 Phase 4
8 Different Day Regimes of Preoperative CONbercept Administration on CytokinEs of Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy: a Prospective Randomized Controlled Clinical Trial (CONCEPT) Unknown status NCT03506750 Phase 4 IVC
9 Three Arm, Prospective, Single-blind, Randomized Study Comparing Ranibizumab Plus Green Diode Laser Versus Ranibizumab Plus Pattern Scan Laser (Pascal) Versus Ranibizumab (Monotherapy) for Proliferative Diabetic Retinopathy. Unknown status NCT02005432 Phase 4 Intravitreal Ranibizumabe;panfotocoagulation (PASCAL);panfotocoagulation (PRP) single shoot (ETDRS)
10 The Effect of Bevacizumab on Peripheral Retinal Changes as Imaged by Wide -Field Fluorescein Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
11 Pilot Study Investigating the Use of Intravitreal Ranibizumab in the Treatment of Vitreous Hemorrhage in Proliferative Diabetic Retinopathy Unknown status NCT01824043 Phase 4 intravitreal ranibizumab injections
12 Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters Unknown status NCT01023698 Phase 4
13 Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes Unknown status NCT01869881 Phase 4 Anplag(Sarpogrelate);Placebo
14 Phase 4 Study of Mechanisms of Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy Unknown status NCT01300273 Phase 4
15 Effect of Aldosterone Antagonism in the Reduction of Albuminuria and Diastolic Disfunction of Patients With Diabetic Nephropathy. Unknown status NCT00870402 Phase 4 Spironolactone;Placebo
16 Prevention of Renal Complications of Diabetes With Thiamine Unknown status NCT01725412 Phase 4
17 Sympathetic Nervous System Inhibition for the Treatment of Diabetic Nephropathy Unknown status NCT01094769 Phase 4 Moxonidine;Placebo
18 Antiproteinuric Effect of Valsartan, Lisinopril and Valsartan Plus Lisinopril in Non-diabetic and Diabetic Renal Disease: a Randomized, Double Blind, Parallel Group, Controlled Trial With 5 Months Follow-up Completed NCT00171574 Phase 4 Valsartan;Valsartan plus HCTZ;Lisinopril
19 Effect of Enalapril and Losartan Association Therapy on Proteinuria and Inflammatory Biomarkers in Diabetic Nephropathy: a Clinical Trial on Type 2 Diabetes Mellitus Completed NCT00419835 Phase 4 enalapril;losartan
20 Effects of Doxazosin on Ambulatory Blood Pressure and Sympathetic Nervous Activity in Hypertensive Patients With Diabetic Nephropathy Completed NCT00295555 Phase 4 Effects of doxazosin on morning surge in diabetic patients
21 Effect of Renin Angiotensin System Blockade on CD95 and ADMA Levels in Type-2 Diabetic Patients With Proteinuria Completed NCT00893425 Phase 4 ramipril
22 A Randomised, Double-blinded, Cross-over Study Investigating the Short-term Impact of Liraglutide on Kidney Function in Diabetic Patients Completed NCT01664676 Phase 4 Liraglutide;Placebo-liraglutide
23 Prospective Randomized Controlled Study of Intravitreal Injection of 0.16 mg Bevacizumab One Day Before Surgery for Proliferative Diabetic Retinopathy Completed NCT01854593 Phase 4 Bevacizumab
24 Different Conbercept Injection Methods in Treatment of Severe Proliferative Diabetic Retinopathy Completed NCT02816710 Phase 4 Conbercept
25 Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy Completed NCT01025934 Phase 4 Bevacizumab
26 Morphological and Functional Retinal Changes Following Retinal Photocoagulation Using a Semiautomated Patterned Scanning Laser System in Proliferative Retinopathy or Macular Edema Secondary to Diabetes Mellitus or Retinal Vein Occlusion Completed NCT00682240 Phase 4
27 Pain Using Reduced Fluence Parameters in Photocoagulation for Diabetic Retinopathy. Completed NCT00802269 Phase 4
28 Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy With New Dense Vitreous Hemorrhage After Full Panretinal Photocoagulation Completed NCT01724385 Phase 4 intravitreal injection of bevacizumab
29 A Randomised, Double-blind, Placebo-controlled, Multicenter Trial to Investigate the Preventive Effect of BIBR277 (Telmisartan) in Diabetic Nephropathy on Transition From Incipient to Overt Nephropathy - Incipient to Overt : Angiotensin 2 Receptor Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION Study - Completed NCT00153088 Phase 4 Telmisartan capsule 40 mg;Placebo;Telmisartan capsule 80 mg
30 Combined Diabetes-Renal Multifactorial Intervention In Patients With Advanced Diabetic Nephropathy (ADN) Completed NCT00708981 Phase 4
31 Spironolactone in Diabetic Nephropathy Completed NCT00317954 Phase 4 Spironolactone
32 A Prospective, Multi-center, Randomized, Open-label, Parallel-arm Controlled Study of Treating Type 2 Diabetic Nephropathy (Stage II-IV) With Alfacalcidol and Irbesartan Completed NCT03147677 Phase 4 Alfacalcidol;Irbesartan
33 A Multicenter, Randomized, Open-label, Parallel-group, Diabetic Diet-controlled Study to Evaluate the Efficacy and Safety of Compound α-Keto Acid Tablet in Combination With LPD in Delaying the Progress of Type 2 Diabetic Nephropathy Completed NCT00363987 Phase 4 Ketosteril®
34 A Randomized, Control, Parallel, Open Label, Multi-centre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy Completed NCT01252056 Phase 4 Probucol;Probucol and Cilostazol
35 Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy Completed NCT00311870 Phase 4 nisoldipine;lisinopril
36 A 28-week, Randomised, Open-label, Parallel-Group, Multi-Center Study To Find the Effective Dose of Candesartan Cilexetil (Atacand) for Renoprotection in Korean Hypertensive Patients With Non-diabetic Nephropathy Completed NCT00573430 Phase 4 Candesartan Cilexetil;Candesartan Cilexetil;Candesartan Cilexetil 32mg
37 A Double-Blind Clinical Trial of Benfotiamine Treatment in Diabetic Nephropathy Completed NCT00565318 Phase 4 Benfotiamine;Placebo
38 Renal Denervation in Patients With Diabetic Nephropathy and Persistent Proteinuria Completed NCT01588795 Phase 4 Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin
39 Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients Completed NCT02628106 Phase 4 Lipo-PGE1
40 "Safety and Efficacy of Acthar Gel on Albuminuria and Urinary Transforming Growth Factor Excretion in Type I or Type II Diabetics Requiring Medical Treatment of Hyperglycemia With Nephrotic Range Proteinuria: A Pilot Study" Completed NCT01028287 Phase 4 ACTH;ACTH
41 Nephropathy in Type 2 Diabetes: Effects of an Intensive Multifactorial Intervention Trial on Cardio-renal Events. Completed NCT00535925 Phase 4 SoC therapy;irbesartan;ramipril;hydrochlorothiazide;furosemide;amlodipine;atenolol;doxazosin;clonidine;insulin;simvastatin;fibrate;erythropoietin;aspirin
42 A Single Arm Open Label Multicenter Interventional Study to Assess the Efficacy, Safety, and Tolerability of Every 4 Weeks Administration of Subcutaneous C.E.R.A. for the Treatment of Chronic Renal Anemia in Diabetic Nephropathy With Chronic Kidney Disease Stages III-IV Not on Dialysis, Not Currently Treated With ESA. Completed NCT01191983 Phase 4 Methoxy polyethylene glycol-epoetin beta [Mircera]
43 A Phase IV, Randomized, Open-Label, Active Controlled Study to Compare the Effects of Tarka® and Lotrel® on Albuminuria in Hypertensive, Type 2 Diabetic Subjects With Diabetic Nephropathy Completed NCT00234871 Phase 4 trandolapril/verapamil;Lotrel (amlodipine/benazepril)
44 Effects of Atorvastatin Versus Probucol on Low-Density Lipoprotein Subtype Distribution and Renal Function in Hyperlipidemic Patients With Non-Diabetic Nephropathy Completed NCT00276133 Phase 4 Effects of atorvastatin versus probucol on small dense LDL
45 A Randomised, Double-Blind, Placebo-Controlled Study of Cilostazol 100 mg Twice Daily in the Treatment of Diabetic Nephropathy in Hong Kong Chinese Completed NCT00272831 Phase 4 Cilostazol;Placebo
46 A Two-Phase Study for Primary and Secondary Prevention of Diabetic Nephropathy by Combined ACE Inhibition and Calcium Channel Blockade (BENEDICT) Completed NCT00235014 Phase 4 trandolapril;trandolapril/verapamil;placebo;verapamil
47 A New Clinical Utility for Tubular Markers to Identify Kidney Responders to Saxagliptin Treatment in Patients With Diabetic Nephropathy Completed NCT04521049 Phase 4 Saxagliptin 5mg
48 Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy: a 24- Week Study Completed NCT02690883 Phase 4 Exenatide;Lispro
49 The Effect of Paricalcitol Versus Placebo on Plasma N-Terminal-proBNP in Patients With Type 1 Diabetes Mellitus and Diabetic Nephropathy Completed NCT01331317 Phase 4 Paricalcitol
50 Comparative Effects of add-on Pentoxifylline to Losartan Versus Increasing Dose of Losartan on Serum NT-PRO BNP and Proteinuria in Type 2 Diabetics With Nephropathy Completed NCT03006952 Phase 4 Pentoxifylline;Losartan

Search NIH Clinical Center for Microvascular Complications of Diabetes 7

Inferred drug relations via UMLS 70 / NDF-RT 51 :


benazepril
Benazepril hydrochloride
candesartan
candesartan cilexetil
Captopril
Enalapril
Enalapril Maleate
Enalaprilat
eprosartan
Eprosartan mesylate
Fosinopril
Fosinopril Sodium
irbesartan
Lisinopril
Losartan
Losartan Potassium
moexipril
Moexipril hydrochloride
olmesartan
Olmesartan medoxomil
Perindopril
Perindopril arginine
Perindopril Erbumine
quinapril
Quinapril hydrochloride
Ramipril
telmisartan
trandolapril
valsartan

Genetic Tests for Microvascular Complications of Diabetes 7

Genetic tests related to Microvascular Complications of Diabetes 7:

# Genetic test Affiliating Genes
1 Microvascular Complications of Diabetes 7 29 HFE

Anatomical Context for Microvascular Complications of Diabetes 7

MalaCards organs/tissues related to Microvascular Complications of Diabetes 7:

40
Kidney, Endothelial, Pancreas, Cortex, Neutrophil, Skin, Bone Marrow

Publications for Microvascular Complications of Diabetes 7

Articles related to Microvascular Complications of Diabetes 7:

(show top 50) (show all 19040)
# Title Authors PMID Year
1
The HFE gene is associated to an earlier age of onset and to the presence of diabetic nephropathy in diabetes mellitus type 2. 6 57 61
15347835 2004
2
Role of hemochromatosis C282Y and H63D mutations in HFE gene in development of type 2 diabetes and diabetic nephropathy. 57 6 61
11423500 2001
3
Prevalence, characteristics, and prognostic significance of HFE gene mutations in type 2 diabetes: the Fremantle Diabetes Study. 6 57
18566337 2008
4
A hemochromatosis-causing mutation C282Y is a risk factor for proliferative diabetic retinopathy in Caucasians with type 2 diabetes. 6 57
14618419 2003
5
Proliferative retinopathy in a patient with diabetes mellitus and idiopathic haemochromatosis. 6 57
678784 1978
6
Variants in TF and HFE explain approximately 40% of genetic variation in serum-transferrin levels. 6
19084217 2009
7
Iron-overload-related disease in HFE hereditary hemochromatosis. 6
18499578 2008
8
Iron-overload-related disease in HFE hereditary hemochromatosis. 6
18504828 2008
9
Frequency of the hemochromatosis gene mutations in the population of Serbia and Montenegro. 6
16879202 2006
10
Association of porphyria cutanea tarda with hereditary hemochromatosis. 6
15280838 2004
11
Hemochromatosis mutations in the general population: iron overload progression rate. 6
15070663 2004
12
Synergy between the C2 allele of transferrin and the C282Y allele of the haemochromatosis gene (HFE) as risk factors for developing Alzheimer's disease. 6
15060098 2004
13
The 16189 variant of mitochondrial DNA occurs more frequently in C282Y homozygotes with haemochromatosis than those without iron loading. 6
14729817 2004
14
Contribution of the H63D mutation in HFE to murine hereditary hemochromatosis. 6
14673107 2003
15
Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis. 6
12915468 2003
16
Hereditary haemochromatosis: only 1% of adult HFEC282Y homozygotes in South Wales have a clinical diagnosis of iron overload. 6
12436244 2002
17
The hemochromatosis protein HFE inhibits iron export from macrophages. 6
12429850 2002
18
Clinical haemochromatosis in HFE mutation carriers. 6
12241803 2002
19
Co-selection of the H63D mutation and the HLA-A29 allele: a new paradigm of linkage disequilibrium? 6
11904676 2002
20
Penetrance of 845G--> A (C282Y) HFE hereditary haemochromatosis mutation in the USA. 6
11812557 2002
21
Identification of an endogenous RNA transcribed from the antisense strand of the HFE gene. 6
11532995 2001
22
Variable phenotypic presentation of iron overload in H63D homozygotes: are genetic modifiers the cause? 6
11358905 2001
23
Spectrum of mutations in the HFE gene implicated in haemochromatosis and porphyria. 6
10401000 1999
24
Polymorphism in intron 4 of HFE may cause overestimation of C282Y homozygote prevalence in haemochromatosis. 6
10431233 1999
25
The C282Y mutation causing hereditary hemochromatosis does not produce a null allele. 6
10381492 1999
26
Celtic origin of the C282Y mutation of hemochromatosis. 6
9851897 1998
27
Hemochromatosis in Ireland and HFE. 6
9851896 1998
28
The hemochromatosis 845 G-->A and 187 C-->G mutations: prevalence in non-Caucasian populations. 6
9585606 1998
29
Targeted disruption of the HFE gene. 6
9482831 1998
30
Phenotype-genotype correlation in haemochromatosis subjects. 6
9439654 1997
31
Hereditary hemochromatosis: effects of C282Y and H63D mutations on association with beta2-microglobulin, intracellular processing, and cell surface expression of the HFE protein in COS-7 cells. 6
9356458 1997
32
A candidate gene for hemochromatosis: frequency of the C282Y and H63D mutations. 6
9341868 1997
33
Homozygosity for the predominant Cys282Tyr mutation and absence of disease expression in hereditary haemochromatosis. 6
9321765 1997
34
The significance of the 187G (H63D) mutation in hemochromatosis. 6
9326341 1997
35
The hemochromatosis founder mutation in HLA-H disrupts beta2-microglobulin interaction and cell surface expression. 6
9162021 1997
36
Mutation analysis of the HLA-H gene in Italian hemochromatosis patients. 6
9106528 1997
37
Global prevalence of putative haemochromatosis mutations. 6
9138148 1997
38
Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. 6
9024376 1997
39
Absence of the hemochromatosis gene Cys282Tyr mutation in three ethnic groups from Algeria (Mzab), Ethiopia, and Senegal. 6
9211748 1997
40
Haemochromatosis and HLA-H. 6
8896549 1996
41
Haemochromatosis and HLA-H. 6
8896550 1996
42
A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. 6
8696333 1996
43
The predictive value of diabetic retinopathy on subsequent diabetic nephropathy in patients with type 2 diabetes: a systematic review and meta-analysis of prospective studies. 61
33478336 2021
44
Urinary calprotectin, NGAL, and KIM-1 in the differentiation of primarily inflammatory vs. non-inflammatory stable chronic kidney diseases. 61
33663323 2021
45
Yishen capsule promotes podocyte autophagy through regulating SIRT1/NF-κB signaling pathway to improve diabetic nephropathy. 61
33427556 2021
46
Medium-term outcomes of multi-disciplinary surgical management of non-ischemic diabetic heel ulcers. 61
33717969 2021
47
Post-operative gastroparesis following carbohydrate loading in a diabetic patient. 61
33644283 2021
48
Increased lipoxygenase and decreased cytochrome P450s metabolites correlated with the incidence of diabetic nephropathy: Potential role of eicosanoids from metabolomics in type 2 diabetic patients. 61
33605471 2021
49
Loganin alleviates macrophage infiltration and activation by inhibiting the MCP-1/CCR2 axis in diabetic nephropathy. 61
33245967 2021
50
An updated pharmacological insight of resveratrol in the treatment of diabetic nephropathy. 61
33631244 2021

Variations for Microvascular Complications of Diabetes 7

ClinVar genetic disease variations for Microvascular Complications of Diabetes 7:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 HFE-AS1 , HFE NM_139011.3(HFE):c.77-2168C>G SNV Pathogenic 10 rs1799945 GRCh37: 6:26091179-26091179
GRCh38: 6:26090951-26090951
2 HFE NM_000410.3(HFE):c.845G>A (p.Cys282Tyr) SNV risk factor 9 rs1800562 GRCh37: 6:26093141-26093141
GRCh38: 6:26092913-26092913
3 HFE-AS1 , HFE NM_139011.3(HFE):c.77-2168C>G SNV risk factor 10 rs1799945 GRCh37: 6:26091179-26091179
GRCh38: 6:26090951-26090951
4 HFE-AS1 , HFE NM_000410.3(HFE):c.193A>T (p.Ser65Cys) SNV Uncertain significance 11 rs1800730 GRCh37: 6:26091185-26091185
GRCh38: 6:26090957-26090957

Expression for Microvascular Complications of Diabetes 7

Search GEO for disease gene expression data for Microvascular Complications of Diabetes 7.

Pathways for Microvascular Complications of Diabetes 7

GO Terms for Microvascular Complications of Diabetes 7

Sources for Microvascular Complications of Diabetes 7

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....